Why Are Oil Prices Still Rising? Only Nine Ships Pass Through the Strait of Hormuz in a Day

Publicado a 2026-08-21Actualizado a 2026-08-21

Resumen

Oil prices have been rising for several consecutive days, so short-term profit-taking is not surprising. However, there are currently few signals that could lower the risk premium: negotiations have not resumed, the number of transits through the Strait remains low, and major Gulf supplies have not returned to normal levels. Compared to new verbal statements, the actual number of ships passing through the Strait of Hormuz each day will more directly determine how much supply premium USOILUSDT can retain next.

Summary

The U.S.-Iran conflict has yet to turn towards a ceasefire, and supply from Gulf oil producers continues to be constrained. Brent and WTI have risen by more than 7% and 8% respectively over the last five trading days. The daily number of vessels passing through the Strait of Hormuz remains far below pre-war levels, with physical flow becoming the main driver pushing oil prices higher.

International oil prices saw little change in early trading on Friday, but the direction for the week was already clear. Reuters data showed that as of early morning Singapore time on August 21, Brent crude futures were trading at $93.82 per barrel, while WTI crude futures were at $86.78 per barrel. In the previous trading session, they had risen by 2.4% and 2.3% respectively.

Extending the timeframe to the preceding five rising trading days, Brent gained more than 7% cumulatively, and WTI rose over 8%, both reaching highs last seen on July 24. Friday's sideways movement seemed more like a digestion of the previous days' gains and did not alter the pattern of oil prices rising for the second consecutive week.

The Market Is Trading on Missing Supply

Behind this rally, the U.S.-Iran war remains the most immediate cause. Previous peace arrangements have expired, and the two sides have not resumed negotiations. U.S. President Trump has again threatened economic retaliation against countries supporting Iran, and the UAE this week also suspended financial and economic dealings with Iran. With no signals of de-escalation, supply from major oil producers like Saudi Arabia, Iraq, the UAE, and Kuwait thus continues to be affected.

War news can change daily, but what oil prices are truly sensitive to is whether this news changes actual loadings, shipping, and export volumes. The current answer still leans towards constrained supply. Since the U.S. and Israel launched military strikes against Iran on February 28, Iran's blockade of the Strait of Hormuz and attacks on energy facilities in the Middle East have disrupted global oil and gas transportation.

Nine Ships a Day, Still Far From Pre-War Levels

Only nine ships passed through the Strait of Hormuz on Wednesday, unchanged from the previous day and well below pre-war levels. Before the war, the volume of oil transported via this waterway accounted for about one-fifth of global consumption. As long as traffic volumes do not recover significantly, the market cannot treat this supply as having been restored.

This explains why oil prices continue to rise even as the conflict is deadlocked. Deadlock does not mean the risk has stopped; on the contrary, it implies that constrained supply could last longer. Refiners and traders need to pay higher costs for alternative sources, detoured transportation, and delivery uncertainties, with near-month contracts reflecting this tension first.

Oil prices have risen for several consecutive days, so short-term profit-taking is not surprising. However, there are currently few signals that could lower the risk premium: negotiations have not resumed, Strait traffic remains low, and major Gulf supply has not returned to normal rhythm. Compared to new verbal statements, the actual daily number of ships passing through the Strait of Hormuz will more directly determine how much supply premium USOILUSDT can retain going forward.

Lecturas Relacionadas

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbitHace 14 min(s)

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbitHace 14 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbitHace 14 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbitHace 14 min(s)

Trading

Spot
活动图片